GPhA welcomes FTC move on biogenerics

Responding to the US Federal Trade Commission's roundtable on Emerging Health Care Competition and Consumer Issues, which addressed follow-on biologic drugs, the Generic Pharmaceutical Association's chief executive, Kathleen Jaeger, said: "the mere fact that the FTC is conducting this roundtable demonstrates the growing momentum behind ensuring that consumers have access to safe and affordable biogenerics sooner rather than later. As our elected officials grapple with issues like market exclusivity and patent resolution measures, they must do so recognizing that competition will unleash innovation, while at the same time assuring that affordable lifesaving medicines are available for patients in need."